Last edition
News about
India Introduces Faster Clinical Trial Timelines to Accelerate Drug Development
If regulatory authorities do not respond within this timeframe, approval is automatically deemed granted, helping to reduce unnecessary delays and providing much-needed certainty to the pharmaceutical sector.
CapVest Acquires Majority Stake in Stada, Abandoning IPO Plans
CapVest Partners, a London-based private equity firm, has agreed to acquire a majority stake in German pharmaceutical company Stada Arzneimittel, effectively halting the drugmaker’s previously explored initial public offering (IPO).
Illuminated Extractors, Ltd., a leader in extraction and thermal management technology, has been granted US Patent US12135149 for its groundbreaking heating and refrigeration system, developed by inventor Zachary Richard Lantz.
Accro Bioscience and Fosun Pharma Enter Licensing Deal for AC-201 in Greater China
Accro Bioscience has granted Fosun Pharma exclusive rights to develop, manufacture, and commercialise AC-201 — its independently developed, highly selective TYK2/JAK1 inhibitor — in Greater China (including the Chinese Mainland, Hong Kong SAR, and Macau SAR).
Pharma Logistics: Sensos Launches GDP-compliant Cellular Smart Label
Sensos’ first fully GDP-compliant cellular smart Label replaces outdated data loggers with a validated solution to ensure compliance.
Foresight Diagnostics, a privately held cancer diagnostics company, has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems, resolving ongoing litigation between the parties. As part of the resolution, all claims against Foresight, its founders, and Stanford University have been dismissed with prejudice.
Piramal Pharma Solutions leveraged its CDMO expertise to help George Medicines develop WIDAPLIK, the first and only FDA-approved triple combination therapy for hypertension, combining telmisartan, amlodipine, and indapamide to effectively lower blood pressure.
Biopharma Firms See 5.7 Percent Market Cap Drop in Q2 2025: Globaldata
Twenty biopharmaceutical companies have reported a 5.7 percent quarter-on-quarter (QoQ) downturn in their combined market capitalisation from USD 3.9 trillion on 31 March, 2025 to USD 3.7 trillion on 30 June, 2025.
AstraZeneca's Baxdrostat Achieves Significant Blood Pressure Reduction in Phase-III Study
The BaxHTN phase-III trial showed Baxdrostat, an investigational drug developed by AstraZeneca, significantly lowered systolic blood pressure in patients with hard-to-control hypertension, achieving both statistical and clinical relevance.
Wegovy Outperforms Tirzepatide, Slashes Cardiovascular Risk by 57 Percent
Wegovy showed a significant 29 percent risk reduction for heart attack, stroke and death from any cause compared with Tirzepatide (over an average follow-up of 8.3 months for Wegovy and 8.6 months for Tirzepatide.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy